Clinical Trial Update: Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating convection-enhanced localized delivery of PRX321 with real-time imaging for recurrent glioblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• PRX321

Snippet

Sponsor: Sophiris Bio Corp | Conditions: Glioblastoma Multiforme | Phase 2 | Status: WITHDRAWN